Research Analysts Offer Predictions for ADCT Q1 Earnings
Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for shares of ADC Therapeutics in a note ...
Orchestra BioMed’s (OBIO) “Buy” Rating Reiterated at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a ...